Protocol Ledger

NCT07282353 · Phase III · RECRUITING

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

Interventional Phase III clinical trial protocol NCT07282353 sponsored by Cascade Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-01 Enrollment: 135 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07282353
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)135 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07282353
Protocol FieldVerified Registry Value
NCT IdentifierNCT07282353
Consolidated Lead SponsorCascade Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment135 participants (ESTIMATED)
Registered Start Date2025-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI